Debate: Best Second-line Approach to Induce Lymphoma Remission Prior to SCT? - Brentuximab

Debate: Value to Using Brentuximab vedotin Consolidation early after Auto-SCT in Hodgkin's? - YesПодробнее

Debate: Recurrent Hodgkin's lymphoma after ASCT in CR on brentuximab vedotin - MaintenanceПодробнее

Debate: Value to Using Brentuximab vedotin Consolidation early after Auto-SCT in Hodgkin's? - NoПодробнее

Debate: Best Second-line Approach to Induce Lymphoma Remission Prior to SCT? - ChemotherapyПодробнее

Debate: Hodgkin lymphoma patient who relapses after autologous SCT - Serial novel agentsПодробнее

Debate: Best second line therapy for relapsed Hodgkin lymphoma - Brentuximab alone/+ chemoПодробнее

Debate: Brentuximab vedotin as upfront therapy for advanced Hodgkin lymphoma? - YesПодробнее

Debate: Best upfront approach for Advanced Stage Hodgkin Lymphoma? - A (brentuximab vedotin) VDПодробнее

Debate: Hodgkin lymphoma patient who remains PET+ at the end of chemotherapy - Radiation therapyПодробнее

Debate: Recurrent Hodgkin's lymphoma after ASCT in CR on brentuximab vedotin - AllotransplantПодробнее

Optimizing Brentuximab Vedotin Use in Hodgkin LymphomaПодробнее

Lymphomas in 2024 Changing Standards of Care and Challenging Paradigms Elizabeth Brem, MD from UCIПодробнее

Debate: Is there a standard second line therapy for HCC? - Regorafenib is a winnerПодробнее

Brentuximab for second-line lymphoma treatmentПодробнее

Debate: Best pre-transplant second line therapy for relapsed Hodgkin lymphoma - Chemo aloneПодробнее

Brentuximab vedotin plus ESHAP: complete remission in R/R Hodgkin lymphomaПодробнее

Debate: Hodgkin lymphoma patient who remains PET+ at the end of chemotherapy - SCT-based therapyПодробнее